HC Wainwright Reaffirms Buy Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)‘s stock had its “buy” rating reissued by HC Wainwright in a research report issued to clients and investors on Tuesday,Benzinga reports. They currently have a $9.00 price objective on the stock.

A number of other research firms have also commented on LCTX. Maxim Group lowered their price objective on shares of Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, January 10th. D. Boral Capital reduced their target price on Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Tuesday.

Lineage Cell Therapeutics Stock Down 2.1 %

LCTX stock traded down $0.01 during trading hours on Tuesday, hitting $0.64. The company’s stock had a trading volume of 379,464 shares, compared to its average volume of 2,166,995. Lineage Cell Therapeutics has a 12 month low of $0.48 and a 12 month high of $1.61. The company has a market capitalization of $141.51 million, a price-to-earnings ratio of -5.34 and a beta of 1.21.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Hedge funds have recently bought and sold shares of the company. Fort Sheridan Advisors LLC boosted its holdings in shares of Lineage Cell Therapeutics by 71.5% in the 4th quarter. Fort Sheridan Advisors LLC now owns 55,177 shares of the company’s stock worth $28,000 after buying an additional 23,000 shares during the last quarter. Atria Wealth Solutions Inc. bought a new position in shares of Lineage Cell Therapeutics in the fourth quarter worth approximately $29,000. HighTower Advisors LLC grew its position in Lineage Cell Therapeutics by 49.5% in the fourth quarter. HighTower Advisors LLC now owns 57,706 shares of the company’s stock worth $29,000 after acquiring an additional 19,100 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of Lineage Cell Therapeutics by 35.5% during the 4th quarter. SG Americas Securities LLC now owns 68,973 shares of the company’s stock valued at $35,000 after buying an additional 18,053 shares in the last quarter. Finally, GSA Capital Partners LLP bought a new position in Lineage Cell Therapeutics during the third quarter valued at approximately $84,000. 62.47% of the stock is owned by hedge funds and other institutional investors.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.